home All News open_in_new Full Article

Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025

Remdantry™ (previously known as Inflectra®), developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar infliximab in Canada and will be commercially available across Canada as of April 1, 2025 Celltrion offers a full-service patient support program offering a wide range of services from financial assistance to patient education in Canada TORONTO — Celltrion, […]


today 8 d. ago attach_file Other

attach_file Other
attach_file Transport
attach_file Society
attach_file Society
attach_file Other
attach_file Economics
attach_file Other
attach_file Other


ID: 351961982
Add Watch Country

arrow_drop_down